The role of lncRNA in cancer biology has recently garnered attention, particularly its involvement in the regulation of gene expression and cancer progression. MALAT1, a prominent lncRNA, has been associated with various malignancies, including multiple myeloma. The current research underscores the relevance of MALAT1 in mediating lenalidomide resistance. By investigating how targeting this lncRNA can reverse resistance mechanisms, the study opens new avenues for therapeutic interventions and could potentially redefine treatment protocols for those affected by this disease.

Lenalidomide, an immunomodulatory drug, has been pivotal in enhancing survival rates among multiple myeloma patients. However, a subset of patients demonstrates resistance, leading to treatment failure and disease progression. Understanding the molecular underpinnings of this resistance is crucial for developing alternative strategies that may facilitate better patient outcomes. The study highlights that by targeting MALAT1, researchers can effectively reduce resistance to lenalidomide, thereby improving its therapeutic efficacy.

The mechanistic insights reveal that MALAT1 exerts regulatory effects on CD38, a cell surface protein that plays a crucial role in immune response modulation. CD38 has been a therapeutic target in multiple myeloma treatment due to its connection with tumor microenvironmental factors. The study elucidates that modulation of CD38 through MALAT1 targeting leads to epigenetic changes that disrupt the cancer-promoting signals, making the tumor cells more susceptible to lenalidomide’s effects.

In addition to its impact on CD38, the research proposes that MALAT1 influences cellular responses to oxidative stress, a condition that results from an imbalance between reactive oxygen species production and antioxidant defenses. Cancer cells often exhibit elevated oxidative stress levels, contributing to their survival and proliferation. By targeting MALAT1, the study shows that oxidative stress-mediated cell death can be enhanced, pushing the cancer cells towards apoptosis and reducing tumor viability.

Furthermore, the remodeling of the pro-tumor microenvironment is a crucial aspect of this research. The tumor microenvironment encompasses the surrounding cells, extracellular matrix, and signaling molecules that support tumor growth and facilitate its resistance to therapies. The findings suggest that by targeting MALAT1, researchers can instigate significant alterations in the pro-tumor microenvironment, shifting it towards a more hostile landscape for malignant cells while potentially enhancing the infiltration and activation of immune cells.

The implications of this research extend into clinical settings, where the study advocates a combination approach that includes targeting lncRNA MALAT1 alongside established therapies like lenalidomide. Such strategies may provide a synergistic effect, counteracting the resistance mechanisms that often hinder treatment efficacy. This notion aligns with the growing interest in personalized medicine, aiming to tailor therapeutic strategies based on individual patient molecular profiles.

The future directions of this research focus on validating the findings in preclinical and clinical models. Moving from bench to bedside requires rigorous testing to ascertain not only the efficacy but also the safety and tolerability of such combinatorial approaches in diverse patient populations. Moreover, longitudinal studies will be essential in understanding the long-term effects of MALAT1 targeting in preventing resistance.

Additionally, the research encourages further exploration into the broader implications of lncRNA in other hematological malignancies and solid tumors. The success of targeting MALAT1 may inspire similar approaches aimed at different lncRNAs implicated in cancer pathology, potentially leading to a new wave of targeted therapies that reshape cancer treatment paradigms.

The interplay between gene expression regulation by lncRNAs and therapeutic responses emphasizes the need for a deeper understanding of these non-coding RNAs. As ongoing research sheds light on the complexity of cancer genomics, innovations in targeted therapy are likely to redefine the landscape of treatment for patients grappling with recalcitrant malignancies.

In conclusion, targeting lncRNA MALAT1 represents a promising frontier in the battle against lenalidomide-resistant multiple myeloma. By unveiling the mechanisms through which MALAT1 influences CD38, oxidative stress responses, and the tumor microenvironment, this study sheds light on potential therapeutic avenues that could enhance treatment efficacy. The findings not only provide hope for enhanced patient outcomes but also underscore the importance of investigating non-coding RNAs in cancer research moving forward.

Ultimately, as the fight against multiple myeloma continues, the insights and strategies proposed by this research may pave the way for new therapeutic landscapes, offering renewed optimism for patients and clinicians alike.

Subject of Research: Targeting lncRNA MALAT1 to combat lenalidomide resistance in multiple myeloma.

Article Title: Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma.

Article References:

Chang, WH., Liao, WT., Yeh, TJ. et al. Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma.
J Transl Med 23, 1199 (2025). https://doi.org/10.1186/s12967-025-07252-1

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07252-1

Keywords: lncRNA, MALAT1, lenalidomide resistance, multiple myeloma, CD38, oxidative stress, tumor microenvironment.

Metabolic complications, including insulin resistance and dyslipidemia, have long shadowed survivors of childhood cancers, manifesting as chronic health burdens in adulthood. Insulin sensitivity, in particular, represents a critical nexus in this pathological cascade, with impaired insulin signaling presaging the development of metabolic syndrome and cardiovascular disease. The APACIS study foregrounds this concern by targeting insulin sensitivity as its primary endpoint, recognizing the compelling need for early interventions that could mitigate long-term sequelae.

At its core, the APACIS protocol innovatively introduces exercise regimens immediately following diagnosis, a strategic departure from traditional approaches that often delay physical activity due to safety concerns during intensive cancer treatment. By randomizing pediatric participants across a spectrum of cancer diagnoses into two exercise intensity groups—one emphasizing low-intensity "Soft" activities and the other engaging in mixed high-intensity "Strong" workouts—the study meticulously evaluates the metabolic repercussions of early and tailored physical interventions over a six-month period.

The Low-Intensity "Soft" group comprises gentle physical activity designed to be feasible and tolerable even amidst treatment side effects, ensuring inclusivity regardless of each child’s fluctuating health status. Conversely, the "Strong" group challenges patients with a regimented mixed exercise routine, incorporating bursts of higher exertion aimed at eliciting more robust physiological adaptations. Both cohorts participate in biweekly sessions lasting between 30 to 60 minutes, fostering consistency while accommodating clinical realities.

Over an ambitious follow-up spanning 18 months, the study employs a rigorous assessment schedule at baseline, 3, 6, 12, and 24 months to track dynamic shifts in metabolic markers and physical fitness indices. Central to this evaluation is the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), a validated proxy of insulin sensitivity derived from fasting glucose and insulin measures. This quantitative approach enables nuanced monitoring of metabolic trajectories in response to personalized exercise stimuli.

Beyond HOMA-IR, APACIS extends its investigative reach to encompass lipid profiles, cortisol concentrations, nutritional status, and a suite of physical performance metrics. Cholesterol and triglyceride levels serve as lipidomic indicators, instrumental in uncovering the cardiometabolic implications of intervention. Cortisol, a biomarker of physiological stress, adds another dimension by elucidating how exercise intensity intersects with hormonal regulation during the taxing cancer treatment journey.

The comprehensive evaluation encapsulates cardiorespiratory fitness through the 6-Minute Walk Test peak oxygen uptake measurement, an accessible yet robust measure of aerobic capacity. Flexibility is gauged via the Sit and Reach test, while anthropometric assessments like Waist-to-Hip Ratio provide insights into fat distribution, a determinant of metabolic health. Patient-reported physical activity levels further contextualize adherence and lifestyle influences, ensuring a holistic analytic framework.

Innovatively, the APACIS protocol integrates advanced metabolomics analyses through a specialized pipeline capable of detecting 150 distinct metabolites. This high-dimensional biochemical profiling facilitates pathway enrichment analyses and metabolic network mapping, elucidating biochemical pathways perturbed by the synergy of cancer and exercise regimens. Such granular metabolic phenotyping promises to uncover mechanistic underpinnings that could guide precision intervention strategies.

The study’s scope also includes cutting-edge microbiota analyses, investigating the oral and intestinal flora subjected to oncologic treatments and modulated by exercise intensity. Dysbiosis and microbial shifts are increasingly recognized contributors to systemic metabolism and immune function, and their interrogation within this trial framework underscores the holistic approach of APACIS to childhood cancer care.

Crucially, the study’s early implementation of exercise interventions signals a paradigm shift, challenging previous hesitations surrounding physical activity initiation during active oncology treatment phases. This proactive stance aspires to harness exercise’s potential to buffer metabolic dysfunction and fortify physical resilience, thereby improving immediate treatment tolerability and long-term health outcomes.

The APACIS trial, registered under ClinicalTrials.gov identifier NCT05383092, signifies a vanguard in pediatric oncology rehabilitation science. By stratifying patients and meticulously quantifying biological and functional endpoints, it bridges a critical knowledge gap concerning optimal exercise prescription tailored to children’s unique physiological and treatment-induced vulnerabilities.

If successful, the findings could ignite a ripple effect across pediatric oncology protocols worldwide, endorsing exercise as a foundational adjunct therapy that transcends traditional supportive care boundaries. Such data-driven guidance would empower clinicians to personalize physical activity recommendations, adjusting intensity to balance efficacy with safety in diverse patient populations.

Moreover, this investigation dovetails with expanding scientific appreciation of exercise as a modulator of systemic metabolism, immune competence, and microbiome composition, all of which bear crucial significance in oncology outcomes. By embedding these analyses within pediatric contexts, APACIS both advances methodological innovation and addresses unmet clinical needs.

Ultimately, the APACIS study ventures beyond conventional metabolism-focused research, embracing an integrative vision that aligns molecular insights with practical rehabilitation strategies. This synergy could redefine survivorship trajectories, mitigating the metabolic toll of childhood cancers and enhancing quality of life through targeted physical engagement.

As the field eagerly anticipates results, the trial underscores the importance of interdisciplinary collaboration among oncologists, exercise physiologists, nutritionists, and molecular biologists. Such a concerted effort ensures that outcomes will not only yield statistical significance but translate into meaningful, actionable recommendations for real-world clinical settings.

In sum, the APACIS study embodies a transformative stride in pediatric cancer care, illuminating the promise of early and tailored exercise interventions to recalibrate the metabolic disruptions wrought by daunting therapies. Its multidimensional approach weaves together physiology, biochemistry, microbiology, and clinical pragmatism—an exemplar of precision medicine applied within the earliest and most critical stages of childhood cancer treatment.

Subject of Research: Investigation of metabolic effects of two levels of exercise intensity on children undergoing cancer treatment, focusing on insulin sensitivity, metabolic profiles, physical fitness, and microbiota.

Article Title: Study protocol of an early randomized intervention trial assessing the metabolic effects of two levels of exercise intensity in children undergoing cancer treatment: the APACIS study

Article References: Thomas, J., Filleron, T., Auriol, F. et al. Study protocol of an early randomized intervention trial assessing the metabolic effects of two levels of exercise intensity in children undergoing cancer treatment: the APACIS study. BMC Cancer 25, 850 (2025). https://doi.org/10.1186/s12885-025-14235-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14235-4